Sodium/glucose cotransporter 2 (SGLT2) inhibitors substantially slow progression of chronic kidney disease and reduce the risk of acute kidney injury, but their effects on kidney physiology are incompletely understood. This study assessed the effects of empagliflozin on a comprehensive set of urinary tubular and glomerular biomarkers.